Navigation Links
Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
Date:10/10/2010

MILAN, ITALY - October 10, 2010 - Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously reported outcomes for patients receiving chemotherapy alone. Dr. Miklos Pless, head of medical oncology at the Winterthur Hospital Cancer center in Switzerland, presented the data at the European Society for Medical Oncology Congress (ESMO).

Physicians delivered TTF Therapy to patients in the study using the NovoTTF-100La portable, non-invasive medical device. Investigators conducted this single arm, phase II study at four centers in Switzerland, enrolling 42 patients with locally advanced and metastatic NSCLC (stage IIIb-IV) who had failed prior treatments with chemotherapy. Patients in the study received TTF Therapy for 12 hours a day in combination with pemetrexed (Alimta; Eli Lilly) until disease progression.

Advanced NSCLC is the second cancer in which TTF Therapy has shown clinical efficacy in human trials. Novocure reported a successful phase III clinical trial of TTF monotherapy in patients with recurrent glioblastoma, an aggressive form of brain cancer, at the American Society for Clinical Oncology Conference (ASCO) earlier this year. Results of this phase III trial have been filed with the U.S. Food and Drug Administration (FDA).

"We were pleased to report on the results of this multi-center trial of TTF Therapy in a non-brain tumor indication," said Dr. Pless. "We believe this study has shown TTF Therapy to be completely non-toxic and to have the potential to act as a significant adjunct to chemotherapy in the treatment of NSCLC and other solid tumor indications."

Patients treated with TTF Therapy in combination with pemetrexed had a median overall survival time of 13.8 months compared with the 8.3 months reported for pemetrexed alone. The one-year survival rate for
'/>"/>

Contact: Anne McPherson
anne.mcpherson@edelman.com
415-486-3273
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related biology news :

1. Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
2. GEN reports on the greening of the life sciences
3. Aware, Inc. Reports Second Quarter 2010 Financial Results
4. GEN reports on rediscovered technology to bolster proteomics research
5. BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results
6. International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit
7. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
8. New climate change reports underscore need for action
9. BIO-key(R) Reports First Quarter 2010 Financial Results
10. Survey reports latest honey bee losses
11. Grupo Radio Centro Reports First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report ... markets for Hand Geometry in US$ Thousands. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... NT APRIL 2010 High in the Mackenzie Mountains, ... being revealed as warming temperatures melt patches of ice that ... Tom Andrews, an archaeologist with the Prince of Wales Northern ... Polar Year Ice Patch Study, is amazed at the implements ...
... April 26, 2010 Energy in, energy out, it,s the ... more than two thirds of Americans classified as overweight or ... Journal of Nutrition Education and Behavior examines how ... loss programs. Researchers at the University of Kentucky and ...
... 26 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader ... (OK) Sheriff,s Office successful deployment of an FBI-compliant advanced authentication solution for ... authentication. , , , ... http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , , , ...
Cached Biology News:Ancient artifacts reveals as northern ice patches melt 2What's motivation got to do with weight loss? 2BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders 2BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders 3BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders 4
(Date:4/23/2015)... 23, 2015 Proove Biosciences ... Medicine, is excited to announce the launch of ... This profile assesses 62 genetic variations to predict ... for commonly prescribed non-opioid pain medications, namely ibuprofen ... alprazolam (brand name Xanax) and acetaminophen (brand name ...
(Date:4/23/2015)... , April 23, 2015 /PRNewswire/ - Crystal Research Associates, ... Informational Overview ® (EIO) on Aeterna Zentaris Inc. ... is available on Crystal Research Associates, website at ... Zentaris, website at www.aezsinc.com . Aeterna ... specialty biopharmaceutical company in oncology, endocrinology, and women,s health. ...
(Date:4/22/2015)... -- The Heinz Family Foundation today announced the winners ... will present unrestricted cash awards totaling $1.25 million ... determination in finding solutions to critical issues both ... include a prolific cartoonist whose quirky characters depict ... two former Marines who are re-engaging veterans in ...
(Date:4/22/2015)... , April 22, 2015   MPIRICA ... today announced $1.6M in Series A financing from ... The funding helps accelerate consumer and employer awareness ... covering surgeries at over 4,800 U.S. hospitals. ... you are probably very concerned about choosing the ...
Breaking Biology Technology:Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 2From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 3From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 4From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 5From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 6MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries 2
... Agreement Enables Spherix to Pursue All Pharmaceutical and Health-Oriented ... June 23 Spherix Incorporated (Nasdaq: SPEX ... a provider of technical and regulatory consulting services to ... it has terminated the 1996 license agreement pursuant to ...
... SAO PAULO, June 23 What does sugarcane have ... successful,30-year experience with sugarcane as a feedstock for ethanol. In ... replace a fossil fuel with,renewable energy has saved some 600 ... years for six billion trees to achieve the same,results. , ...
... , Continuing Supplies Will Be Used For NDA and ... Type 2 Diabetes , , BETHESDA, Md., June ... an innovator in biotechnology for diabetes therapy, and a ... supplement, biotechnology and pharmaceutical companies, today announced that it ...
Cached Biology Technology:Spherix Announces Termination of Arla License Agreement 2Spherix Announces Termination of Arla License Agreement 3Spherix Announces Termination of Arla License Agreement 4Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 2Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 3Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 4Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 2Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 3Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 4
... GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H ... 6 ,M.W.= 408.63 ,Assay: Greater ... in DMF) ,Biological Activity: Blue color ... Analysis: Agrees with theoretical values ,Thin ...
BD IMagnet 1 each...
... and M.W. Turner (1997). • This ... used in the production of high-quality ... immunoassays, the standardisation of antibodies and ... amplification systems, enzyme immunoassays for detecting ...
MitoScreen (JC-1) Kit , 100 tests Consult technical datasheet for details....
Biology Products: